

Associate, Wilmington

Corporate Restructuring



T: 302.651.3048  
jacqueline.dakin@skadden.com

## Education

J.D., Villanova University Charles Widger School of Law, 2019  
(*summa cum laude*; Order of the Coif; Member, *Villanova Law Review*)

B.A., University of Connecticut, 2016  
(*magna cum laude*)

## Bar Admissions

Delaware

Jacqueline Dakin represents debtors, creditors, investors and other stakeholders in complex business reorganizations and distressed transactions, including Chapter 11 reorganizations, out-of-court workouts, M&A transactions and other related financing and restructuring matters. She also advises clients on general corporate and litigation matters.

Ms. Dakin's experience includes counseling, among others:

- Endo International plc and certain of its affiliates in their Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of New York
- Armstrong Flooring, Inc. and three affiliated debtors in their Chapter 11 cases in the U.S. Bankruptcy Court for the District of Delaware, including the \$107 million sale of Armstrong's North American assets, the \$59 million sale of its assets in China and Hong Kong and the \$31 million sale of its assets in Australia
- Highline Management Inc. in connection with the \$880 million sale of substantially all of the assets of Prime Automotive Group to Group 1 Automotive, Inc.
- Black Diamond Capital Management, L.L.C. as lender to, and potential purchaser of, Speedcast International Ltd. in its Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas
- The McClatchy Company and certain of its affiliates in their Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of New York, including the \$312 million sale of substantially all of its assets to its largest bondholder, Chatham Asset Management
- Patriarch Partners in connection with multiple matters, including the restructuring of Dura Automotive in the U.S. Bankruptcy Court for the District of Delaware
- the special litigation committee of Clovis Oncology Inc. in an 18-month internal investigation and successful resolution of high-profile *Caremark* claims